Navigation Links
RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study
Date:7/12/2013

WESTBOROUGH, Mass., July 12, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA® compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.

In this study, subjects received small skin incisions in their abdomen and were treated with 3 intradermal doses of RXI‑109 over a 2-week period.  This dose escalating study consisted of 3 cohorts of 3 healthy volunteers each.  Subjects received RXI‑109 on one side of the abdomen, and placebo on the other side. Subjects were monitored for safety and local and systemic side effects over a total study period of 84 days. Multiple dermal injections were well tolerated at all doses, and treatment with RXI‑109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas.

Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals said that, "We are very pleased with the outcome of this second Phase 1 study.  These results show that multiple intradermal injections of RXI‑109 are well tolerated with minimal and mild side effects. He added that, "The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action. Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI‑109 as compared to placebo. Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great  promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.


'/>"/>
SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. UCBs Kremers Urban Pharmaceuticals Inc. receives FDA approval for extended release methylphenidate hydrochloride
2. Tris Pharmas Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
3. Breckenridge Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macovens Discontinuance of Certain Products
4. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
5. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
6. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
7. Vanda Pharmaceuticals, Inc. Sued by Investor
8. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares
10. Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice
11. Oramed Pharmaceuticals to Present Findings on Oral Insulin to the American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016   Acsis , a leading provider of ... market research and advisory firm IDC has named it ... Worldwide Pharmaceutical Track and Trace Software 2016 Vendor Assessment ... assessment of the capabilities and business strategies of 10 ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/28/2016)... , April 28, 2016 ... development of innovative peptide and gene-based immunotherapeutics and vaccines for ... will be presenting at the 3rd Annual Growth Capital ... 5 th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... am on Wednesday, May 4 th by Dr. ...
(Date:4/27/2016)... April 27, 2016  Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended March ... of $0.24 increased 41.2%, and non-GAAP diluted EPS ... increased 5.8% on a reported basis, and 6.3% ... "We posted another good quarter, highlighted by 14.6% ...
Breaking Medicine Technology:
(Date:4/28/2016)... Thousand Oaks, CA (PRWEB) , ... April 28, 2016 , ... ... brand is currently number one in Central America and is looking to grow their ... provide marketing for such an exceptional brand as La Sirena Foods and ...
(Date:4/28/2016)... ... April 28, 2016 , ... Head Over Heels Athletic Arts’ gymnast, ... The competition will be held at the University of Montana on April 28-May 1. ... the Mississippi River. , In order to qualify, Varize needed to place top seven ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... open availability of a new CDISC standard, Clinical Trial Registry (CTR) XML. ... This innovative standard will make it possible to build applications that generate ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cosmetic Town, an online plastic surgery ... The forum section was recently revamped and upgraded to allow even more interaction between ... across the country. , According to the senior editor of Cosmetic Town, “We are ...
(Date:4/28/2016)... Beach, FL (PRWEB) , ... April 28, 2016 , ... ... the spring season. Smart pots are frequently used by professional organic farmers and nurseries ... growers to order their supply of fabric pots. Our goal is to offer wholesale ...
Breaking Medicine News(10 mins):